Floatz logo

Cnct19

Relapsed or Refractory Acute Lymphoblastic Leukemia

Juventas Cell Therapy Ltd.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

252 Active assets in the Relapsed or Refractory Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
Daunorubicin
PETHEMA Foundation
Phase 4BB

View all 50 →

Same molecule, other indications

Cnct19 is also rated in:

large B-cell lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
non-Hodgkin lymphomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →